AP1903

DRUG9 trials

Sponsors

Bellicum Pharmaceuticals, Baylor College of Medicine, M.D. Anderson Cancer Center, National Cancer Institute (NCI), Memorial Sloan Kettering Cancer Center

Conditions

Acute Lymphoblastic LeukemiaAcute Lymphocytic LeukemiaAcute Myeloid LeukemiaB-Lymphoid MalignanciesBreast CancerCastrate Resistant Prostate Cancer (CRPC)Chronic Lymphocytic LeukemiaChronic Myelogenous Leukemia

Phase 1

MTD Study of Vaccine BP-GMAX-CD1 Plus AP1903 to Treat Castrate Resistant Prostate Cancer

CompletedNCT00868595

Bellicum PharmaceuticalsCastrate Resistant Prostate Cancer (CRPC)

Start: 2009-04-30End: 2012-03-31Updated: 2019-10-08

Administration of Donor T Cells With the Caspase-9 Suicide Gene

Active, not recruitingNCT01494103

Baylor College of MedicineAcute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myelogenous Leukemia +7

Start: 2011-11-30End: 2029-05-31Updated: 2025-07-11

Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene

TerminatedNCT01875237

M.D. Anderson Cancer CenterLeukemia, Myeloma, Myeloproliferative Diseases

Start: 2013-12-27End: 2017-03-07Updated: 2019-07-16

A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors

CompletedNCT02107963

National Cancer Institute (NCI)Melanoma, Neuroblastoma, Osteosarcoma +1

Start: 2014-02-28End: 2017-01-31Updated: 2024-05-16

Safety Study of Gene Modified Donor T-Cells in Adults With Advanced Hematologic Malignancies

WithdrawnNCT02487459

Bellicum PharmaceuticalsHematologic Malignancies

Start: 2016-07-31End: 2017-06-30Updated: 2020-10-05

T-Cell Therapy for Advanced Breast Cancer

Active, not recruitingNCT02792114

Memorial Sloan Kettering Cancer CenterBreast Cancer, Metastatic HER2-negative Breast

Start: 2016-06-30End: 2026-06-30Updated: 2025-07-17

Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies

CompletedNCT03056339

M.D. Anderson Cancer CenterAcute Lymphocytic Leukemia, B-Lymphoid Malignancies, Chronic Lymphocytic Leukemia +1

Start: 2017-06-21End: 2023-03-06Updated: 2024-03-25

Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma

Active, not recruitingNCT03696784

UNC Lineberger Comprehensive Cancer CenterImmune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases +2

Start: 2019-03-12End: 2040-07-31Updated: 2025-12-08

Unknown Phase

Compassionate Use of CAR T Cells Targeting the CD19 Antigen and Containing the Inducible Caspase 9 Safety Switch

UNC Lineberger Comprehensive Cancer CenterAcute Lymphoblastic Leukemia, Immune System Diseases, Immunoproliferative Disorders

Updated: 2021-12-03

Related Papers

Abstract 141: Selecting cord blood-derived NK cells enriched in mature subsets optimizes CAR-NK cell-based anti-tumor therapy.

Cancer Research2026-04-03

Recent Advancements in Cell-Based Therapies in Melanoma.

2024-09-124 citations

Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial

Nature Medicine2024-01-18363 citations

Immune determinants of CAR-T cell expansion in solid tumor patients receiving GD2 CAR-T cell therapy.

2023-12-2168 citations

Deep myeloid cell profiling provides new insights into modulators of CAR T cell expansion in patients with pediatric solid tumors

The Journal of Immunology2023-05-01

Abstract 2142: Immune determinants of CAR-T expansion in solid tumor patients receiving GD2 CAR-T cell therapy

Cancer Research2023-04-04

397 Deep myeloid cell profiling provides new insights into modulators of CAR T cell expansion in patients with solid tumor malignancies

Regular and Young Investigator Award Abstracts2022-11-012 citations

362 Defining T cell exhaustion and memory correlates of GD2 CAR T cell expansion in pediatric patients with solid tumor malignancies

Regular and Young Investigator Award Abstracts2022-11-01

Abstract CT142: GD2.Ox40.CD28.z CAR T cell trial in neuroblastoma and osteosarcoma

Cancer Research2022-06-155 citations

Global Perspective on the Development of Genetically Modified Immune Cells for Cancer Therapy.

2021-02-156 citations

CD19 positive lymphoide Malignome: CAR-transduzierte natürliche Killerzellen nutzen

Kompass Onkologie2021-01-01

Phase II study of concomitant radiotherapy with atezolizumab in oligometastatic soft tissue sarcomas: STEREOSARC trial protocol

BMJ Open2020-09-0113 citations

Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors

New England Journal of Medicine2020-02-051995 citations

Immunotherapeutic Approaches in Acute Leukemias

Oncology Times2019-11-261 citations

Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation

Blood2015-05-15214 citations